Answers are grounded in this paper and cite their sources.
Phase 2 trial shows improved MRD-negativity rates in adults with acute lymphoblastic leukemia, suggesting effective therapy.
Inotuzumab ozogamicin, an anti-CD22 antibody-drug conjugate, has demonstrated high response rates and measurable residual disease (MRD)-negativity in acute lymphoblastic leukemia (ALL). This phase 2 single-center study evaluated inotuzumab 0.6 mg/m 2 day 1 and 0.3 mg/m 2 day 8 (cycle 1) followed by 0.3 mg/m 2 days 1 and 8 (cycles 2–6) for adults with B-cell ALL in morphologic remission with detectable MRD (≥1 × 10 −4 by multiparameter flow cytometry, BCR::ABL1 transcripts ≥0.01% by polymerase chain reaction [PCR], or ≥1 × 10 −6 by next-generation sequencing [NGS]). Thirty-seven patients (median age 49 years) were treated, including 17 with Philadelphia-chromosome (Ph)-negative ALL and 20 with Ph-positive ALL. Twenty-eight patients (76%) were in first remission (CR1). Overall, 26 patients (70%) achieved MRD-negativity, including 76% of patients with Ph-negative ALL and 65% of patients with Ph-positive ALL. The NGS MRD-negativity rate was 73%. With a median follow-up of 50 months, the median overall survival (OS) was 61 months, with a median relapse-free survival (RFS) of 40 months. Patients treated in CR1 vs CR2+ had a median OS that was not reached versus 14 months, respectively ( p = 0.056). Three cases (8%) of non-fatal sinusoidal obstructive syndrome (SOS) were observed. Inotuzumab was safe and effective at eradicating MRD.
No takes yet. Share an insight, caveat, or question.
Jabbour et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: